Pfizer ex-chemist launches thyroid eye disease treatment startup with $95M

Health

A former Pfizer chemist has founded Khartis Therapeutics with $95 million to develop an oral pill for thyroid eye disease. The startup’s current status is pre-clinical, meaning the treatment has not yet entered human trials. If successfully developed, this approach could improve accessibility for a condition affecting thousands of people globally. However, the treatment remains experimental and not yet available to patients. The source provides no details about clinical progress timelines or patient impact metrics. This signal is thin: the metadata describes the startup’s launch and funding but offers no evidence of current progress or near-term availability. A reader must consult the original source for how close this work is to real-world application.

Source: Fierce Biotech